In a systematic review and meta-analysis, investigators found that liposomal bupivacaine, an extended-release local anesthetic designed to prolong postoperative pain control, may offer limited clinical benefit in patients undergoing third molar extraction despite modest reductions in opioid use.
Third molar extraction is often associated with significant postoperative pain and frequent opioid prescribing. “[D]ental-related pain remains the second most frequent cause of immediate-release opioid prescriptions,” stated lead study author Mohammed Aljumaiaan, DDS, of the Department of Dentistry at the Salwa Specialized Center Polyclinic at the Ministry of Health in Kuwait, and colleagues, underscoring the need for effective nonopioid pain management strategies.
To evaluate liposomal bupivacaine's efficacy, the investigators analyzed four studies comprising 858 participants. The analysis compared liposomal bupivacaine with standard bupivacaine or placebo, focusing on postoperative pain outcomes and opioid consumption.
The results showed that liposomal bupivacaine was associated with a statistically significant reduction in opioid consumption at 48 hours. However, the magnitude of this reduction was small. Specifically, the meta-analysis found a decrease of −1.20 morphine mg equivalents (MME). As a result, the investigators indicated that liposomal bupivacaine's ability to reduce postoperative opioid use was clinically negligible.
One included study reported a larger reduction in opioid prescriptions, but this finding wasn't consistently reflected in actual opioid consumption. The investigators highlighted this discrepancy.
“The reduction in prescriptions might be a behavioral phenomenon, not a pharmacologic one,” they noted.
Further, liposomal bupivacaine didn't significantly improve postoperative pain outcomes. The pooled analysis found “no statistically significant difference in postoperative pain intensity between [liposomal bupivacaine] and controls in the first 48 hours,” and no meaningful difference in cumulative pain scores. The study authors added that “the prolonged-release formulation did not translate to superior analgesia in the critical acute phase.”
The findings could challenge the theoretical advantage of liposomal bupivacaine's extended-release design, which is intended to provide analgesia for up to 72 to 96 hours.
“Our results did not reveal convergence between the assumed pharmacokinetic benefits and the actual clinical performance,” the study authors said.
The analysis also identified substantial variability across the studies, particularly in cumulative pain outcomes, and emphasized the limited number of available trials. As a result, the investigators urged caution in interpreting the findings and called for further research.
From a clinical perspective, the study suggested that routine use of liposomal bupivacaine for third molar extraction may not be justified, particularly given its cost and lack of clear superiority over standard treatments.
“While [liposomal bupivacaine] provides a statistically significant reduction in opioid consumption, the effect size is clinically irrelevant,” the study authors emphasized. “Further, larger transparent [randomized control trials] are needed to support its role,” they concluded.
The evidence could raise questions about its routine use in this setting.
The study authors reported no conflicts of interest.
Source: Cureus
